InMed Pharmaceuticals raises $5.2M through private placement and option exercise

InMed Pharmaceuticals Inc.

Gross proceeds ~$5.2M from sale of 3,012,049 pre-funded warrants and options; existing holders exercised 3,272,733 options at $0.83.
Issued new preferred investment options to purchase up to 6,545,466 shares at $0.83, exercisable immediately, expire in 5.5 years.
H.C. Wainwright acted as exclusive placement agent; received 7.5% cash fee and warrants for 408,511 shares at $1.0375.
Proceeds to fund pipeline development, BayMedica commercial sales, and general working capital.
Securities unregistered; company to file resale registration statement within 50-80 days of closing.

item 1.01 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

InMed Pharmaceuticals Inc. entered into Purchase Agreement with two institutional accredited investors.

Action: entry
Agreement: equity purchase
Counterparty: two institutional accredited investors

Exact text from the filing

On October 24, InMed Pharmaceuticals Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with two institutional accredited investors (the “Purchasers”), for the sale and issuance of an aggregate of 3,012,049 of its common shares (or pre-funded warrants in lieu thereof) at a purchase price of $0.83 per share (or pre-funded warrant in lieu thereof).

View on SEC.gov

197 material agreements filed in the last 30 days. Browse all material agreements →

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001013762-23-007388

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.